Fig. 1From: Erenumab and galcanezumab in chronic migraine prevention: effects after treatment terminationMonthly migraine days during baseline, the last 4 weeks of open-label extension (OLE) and the observation period of 12 weeks-following OLE completion (pooled data). * = significant vs. baselineBack to article page